Skip to Main Content
DownloadHi-Res Photo

Ali Abu-Alfa

MD, FASN, FAHA
Assistant Professor Adjunct; Director, Joint CME Sponsored Educational Programs; Head, AUB Division of Nephrology and Hypertension; Director, AUB Human Research Protection Program; Director, AUB Medical Center Research Affairs Office; Chair, AUBMC Pharmacy and Therapeutics Committee; Chair, AUBMC Organ Transplantation Committee; Ex-Officio, AUB Clinical Research Institute

Contact Information

Ali Abu-Alfa, MD, FASN, FAHA

Mailing Address

  • Section of Nephrology

    PO Box 208029, 330 Cedar Street

    New Haven, CT 06520-8029

    United States

Research Summary

My primary research interests are:

  1. The delivery and methods of peritoneal dialysis as well as patient choice in renal replacement therapy.
  2. Nephrogenic Systemic Fibrosis and Gadolinium Containing Contrast Agents. focusing on epidemiology, mechanism of disease, policy and risk reduction.
  3. Optimizing the care of patients with chronic kidney disease with particular focus on anemia management and treatment of CKD-Mineral Bone Disorders.
  4. Glomerular diseases and genetic basis for familial clustering in Lebanon and surrounding countries.
  5. Evaluation of barriers to SGLT2 inhibitors use in chronic kidney disease.

Extensive Research Description

I am primarily interested in improving the delivery and methods of peritoneal dialysis, as part of improving delivery of care and increasing accessibility to the therapy in both resource-rich and resource-limited settings. Use of PD in Lebanon is centralized through a unique setup with a private vendor, which may offer advantages but needs to be formally studies as to outcomes, cost, growth and satisfaction. A study is being launched soon having secured access to the rich dataset spanning over 2 decades from the vendor under AUB auspices and governance by its IRB. Findings should help guide advocacy efforts for PD on a larger scale especially in low-resource settings, Given that 15 million patients in need of kidney replacement therapy will not have access to it in 2030 worldwide, solutions such as cheaper PD has been a focus for both the International Society for Peritoneal Dialysis and the International Society of Nephrology.

I have maintained a long-standing interest in optimizing the care of patients with chronic kidney disease (CKD) with particular focus on anemia management and CKD-MBD, and on the transition to the renal replacement therapy phase. Another long-standing interest has also been on Gadolinium-based Contrast Agents and their use in renal patients, focusing on risk reduction and updating policies, watching for any new adverse events now that Nephrogenic Systemic Fibrosis has essentially disappeared.

More recently, and with some funding becoming available, I rekindled our group's interest in studying glomerular diseases and the genetic basis for familial clustering we commonly seen in our practice at AUB, caring for patients from Lebanon as well as from surrounding countries with even higher consanguinity rates. A project has now moved to execution phase starting with establishment of a registry. A large number of biopsies have been sent to Yale for Electron Microscopy evaluation since 2012 which provide strong basis for diagnostic accuracy. Collaboration is planned with the Nephrology team at Yale as work progresses. Similar work was started for Polycystic Kidney Disease with an already launched prospective registry.

Finally, and with the clear benefit of using SGLT2 inhibitors in CKD, including in non-diabetic patients, a study is being readied to examine barriers to the use of this new class of medications, through AUBHealth-EPIC.

Coauthors

Research Interests

Gadolinium; Hypertension; Peritoneal Dialysis; Chronic Kidney Disease-Mineral and Bone Disorder; Nephrogenic Fibrosing Dermopathy

Public Health Interests

Health Policy

Selected Publications

  • Framework for establishing integrated kidney care programs in low- and middle-income countries.Tonelli M, Nkunu V, Varghese C, Abu-Alfa AK, Alrukhaimi MN, Fox L, Gill J, Harris DCH, Hou FF, O'Connell PJ, Rashid HU, Niang A, Ossareh S, Tesar V, Zakharova E, Yang CW. Framework for establishing integrated kidney care programs in low- and middle-income countries. Kidney International Supplements 2020, 10: e19-e23. PMID: 32149006, PMCID: PMC7031683, DOI: 10.1016/j.kisu.2019.11.002.
  • Considerations on equity in management of end-stage kidney disease in low- and middle-income countries.Van Biesen W, Jha V, Abu-Alfa AK, Andreoli SP, Ashuntantang G, Bernieh B, Brown E, Chen Y, Coppo R, Couchoud C, Cullis B, Douthat W, Eke FU, Hemmelgarn B, Hou FF, Levin NW, Luyckx VA, Morton RL, Moosa MR, Murtagh FEM, Richards M, Rondeau E, Schneditz D, Shah KD, Tesar V, Yeates K, Garcia Garcia G. Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney International Supplements 2020, 10: e63-e71. PMID: 32149010, PMCID: PMC7031686, DOI: 10.1016/j.kisu.2019.11.004.
  • Increasing access to integrated ESKD care as part of universal health coverage.Harris DCH, Davies SJ, Finkelstein FO, Jha V, Donner JA, Abraham G, Bello AK, Caskey FJ, Garcia GG, Harden P, Hemmelgarn B, Johnson DW, Levin NW, Luyckx VA, Martin DE, McCulloch MI, Moosa MR, O'Connell PJ, Okpechi IG, Pecoits Filho R, Shah KD, Sola L, Swanepoel C, Tonelli M, Twahir A, van Biesen W, Varghese C, Yang CW, Zuniga C. Increasing access to integrated ESKD care as part of universal health coverage. Kidney International 2019, 95: S1-S33. PMID: 30904051, DOI: 10.1016/j.kint.2018.12.005.
  • International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East.Amouzegar A, Abu-Alfa AK, Alrukhaimi MN, Bello AK, Ghnaimat MA, Johnson DW, Jha V, Harris DCH, Levin A, Tonelli M, Lunney M, Saad S, Khan M, Zaidi D, Osman MA, Ye F, Okpechi IG, Ossareh S. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East. Kidney International Supplements 2021, 11: e47-e56. PMID: 33981470, PMCID: PMC8084726, DOI: 10.1016/j.kisu.2021.01.002.
  • Strategic plan for integrated care of patients with kidney failure.Harris DCH, Davies SJ, Finkelstein FO, Jha V, Bello AK, Brown M, Caskey FJ, Donner JA, Liew A, Muller E, Naicker S, O'Connell PJ, Filho RP, Vachharajani T. Strategic plan for integrated care of patients with kidney failure. Kidney International 2020, 98: S117-S134. PMID: 33126957, DOI: 10.1016/j.kint.2020.07.023.
  • Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) Consensus Workshop.Manera KE, Johnson DW, Craig JC, Shen JI, Gutman T, Cho Y, Wang AY, Brown EA, Brunier G, Dong J, Dunning T, Mehrotra R, Naicker S, Pecoits-Filho R, Perl J, Wilkie M, Tong A, SONG-PD Workshop Investigators.. Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) Consensus Workshop. Am J Kidney Dis 2020, 75:404-412.
  • Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change.Abu-Alfa AK. Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 2020, 76: 436-439. PMID: 32283121, DOI: 10.1053/j.ajkd.2020.03.011.
  • Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD PatientsAbu-Alfa, AK. Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY. Kidney360. 2021;2(1):16-19.
  • Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report.Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE, Abu-Alfa AK, Miller FH, Godinez-Puig V, Dharnidharka VR, West DP. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric Radiology 2014, 44: 173-80. PMID: 24057195, PMCID: PMC3946726, DOI: 10.1007/s00247-013-2795-x.
  • Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. The British Journal Of Radiology 2014, 87: 20140307. PMID: 25230161, PMCID: PMC4170864, DOI: 10.1259/bjr.20140307.
  • Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. Journal Of The American Academy Of Dermatology 2011, 65: 1095-1106.e7. PMID: 21724294, DOI: 10.1016/j.jaad.2010.08.041.
  • Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, Małyszko J, Swinkels DW, Tarng DC, Cheung M, Jadoul M, Winkelmayer WC, Drüeke TB, Conference Participants.. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 2021, 99:1280-1295.
  • KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation.Małyszko J, Bamias A, Danesh FR, Dębska-Ślizień A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Porta C, Conference Participants.. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney Int 2020, 98:1407-1418.
  • KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer.Porta C, Bamias A, Danesh FR, Dębska-Ślizień A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Małyszko J, Conference Participants.. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int 2020, 98: 1108-1119. PMID: 33126977, DOI: 10.1016/j.kint.2020.06.046.
  • Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, McCullough PA, Conference Participants.. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019, 95:1304-1317.
  • Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Chan CT, Blankestijn PJ, Dember LM, Gallieni M, Harris DCH, Lok CE, Mehrotra R, Stevens PE, Wang AY, Cheung M, Wheeler DC, Winkelmayer WC, Pollock CA, Conference Participants.. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019, 96:37-47.
  • Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR, Conference Participants.. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2018, 93:1281-1292.
  • Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, Post FA, Wearne N, Winkler CA, Cheung M, Wheeler DC, Winkelmayer WC, Wyatt CM, Conference Participants.. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2018, 93:545-559.
  • Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, Pfeffer MA, Rossing P, Walsh M, Wanner C, Wheeler DC, Winkelmayer WC, McMurray JJV, KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants.. Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017, 92:297-305.
  • May Measurement Month 2019: an analysis of blood pressure screening results from Lebanon.Najem RN, Halawi A, Tanios B, Ambriss R, Bikai RE, Partington G, Beaney T, Poulter NR, Alfa AKA. May Measurement Month 2019: an analysis of blood pressure screening results from Lebanon. European Heart Journal Supplements : Journal Of The European Society Of Cardiology 2021, 23: B92-B94. PMID: 34248434, PMCID: PMC8263084, DOI: 10.1093/eurheartj/suab037.
  • May Measurement Month 2019: The Global Blood Pressure Screening Campaign of the International Society of Hypertension.Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, Cro S, Diaz A, Damasceno A, Espeche W, Jose AP, Khan N, Kokubo Y, Maheshwari A, Marin MJ, More A, Neupane D, Nilsson P, Patil M, Prabhakaran D, Ramirez A, Rodriguez P, Schlaich M, Steckelings UM, Tomaszewski M, Unger T, Wainford R, Wang J, Williams B, Poulter NR, MMM Investigators*.. May Measurement Month 2019: The Global Blood Pressure Screening Campaign of the International Society of Hypertension. Hypertension 2020, 76:333-341.
  • May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension.Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, Kruger R, Nilsson PM, Prabhakaran D, Ramirez AJ, Schlaich MP, Schutte AE, Tomaszewski M, Touyz R, Wang JG, Weber MA, Poulter NR, MMM Investigators.. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J 2019, 40:2006-2017.
  • Hypertensive Encephalopathy and Renal Failure in a Young Man.Hunter RW, Dominiczak AF, Alwakeel J, Staessen JA, Jennings GL, Abu-Alfa AK, Webb DJ, Dhaun N. Hypertensive Encephalopathy and Renal Failure in a Young Man. Hypertension 2016, 67: 6-13. PMID: 26597825, DOI: 10.1161/HYPERTENSIONAHA.115.06651.
  • Collagenofibrotic glomerulopathy in a kidney transplant recipient: A first report.Jdiaa SS, Moeckel GW, Kfoury Kassouf H, Medawar WA, Abu-Alfa AK. Collagenofibrotic glomerulopathy in a kidney transplant recipient: A first report. American Journal Of Transplantation : Official Journal Of The American Society Of Transplantation And The American Society Of Transplant Surgeons 2021, 21: 1948-1952. PMID: 33206467, DOI: 10.1111/ajt.16399.
  • The Case | Severe high-anion gap metabolic acidosis.Jdiaa SS, Abu-Alfa AK. The Case | Severe high-anion gap metabolic acidosis. Kidney International 2020, 98: 1625-1626. PMID: 33276873, DOI: 10.1016/j.kint.2020.06.013.
  • Hungry bone syndrome two weeks after starting cinacalcet: a call for caution.Koubar SH, Qannus AA, Medawar W, Abu-Alfa AK. Hungry bone syndrome two weeks after starting cinacalcet: a call for caution. CEN Case Reports 2018, 7: 21-23. PMID: 29124559, PMCID: PMC5886916, DOI: 10.1007/s13730-017-0284-z.
  • Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.Edwards BJ, Usmani S, Raisch DW, McKoy JM, Samaras AT, Belknap SM, Trifilio SM, Hahr A, Bunta AD, Abu-Alfa A, Langman CB, Rosen ST, West DP. Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project. Journal Of Oncology Practice / American Society Of Clinical Oncology 2013, 9: 101-6. PMID: 23814519, PMCID: PMC3595436, DOI: 10.1200/JOP.2011.000486.
  • Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients.Abou-Mrad RM, Abu-Alfa AK, Ziyadeh FN. Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients. American Journal Of Physiology. Renal Physiology 2013, 305: F613-7. PMID: 23825072, DOI: 10.1152/ajprenal.00173.2013.
  • Non-uremic calcific arteriolopathy (calciphylaxis) in relapsed/refractory Hodgkin's lymphoma: a previously unreported association.Sibai H, Ishak RS, Halawi R, Otrock ZK, Salman S, Abu-Alfa A, Kharfan-Dabaja MA. Non-uremic calcific arteriolopathy (calciphylaxis) in relapsed/refractory Hodgkin's lymphoma: a previously unreported association. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2012, 30: e88-90. PMID: 22231039, DOI: 10.1200/JCO.2011.39.4551.
  • Hepatocellular carcinoma following renal transplantation.Ang C, Abu-Alfa AK, Abdullah K, Lowery M, Sibai H, El Farran H, Tamraz S, Al Olayan A, Shamseddine A, Naghy M, Faraj W, O'Reilly EM, Abou-Alfa GK. Hepatocellular carcinoma following renal transplantation. Gastrointestinal Cancer Research : GCR 2011, 4: 180-3. PMID: 22295131, PMCID: PMC3269137.
  • Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?Weinreb JC, Abu-Alfa AK. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? Journal Of Magnetic Resonance Imaging : JMRI 2009, 30: 1236-9. PMID: 19938035, DOI: 10.1002/jmri.21979.
  • Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature.Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology, Dialysis, Transplantation : Official Publication Of The European Dialysis And Transplant Association - European Renal Association 2011, 26: 1099-101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.
  • Systematic barriers to the effective delivery of home dialysis in the United States: a report from the Public Policy/Advocacy Committee of the North American Chapter of the International Society for Peritoneal Dialysis.Golper TA, Saxena AB, Piraino B, Teitelbaum I, Burkart J, Finkelstein FO, Abu-Alfa A. Systematic barriers to the effective delivery of home dialysis in the United States: a report from the Public Policy/Advocacy Committee of the North American Chapter of the International Society for Peritoneal Dialysis. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 2011, 58: 879-85. PMID: 21903316, DOI: 10.1053/j.ajkd.2011.06.028.
  • Nephrogenic systemic fibrosis and gadolinium-based contrast agents.Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Advances In Chronic Kidney Disease 2011, 18: 188-98. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.
  • Experience with outpatient computed tomographic-guided renal biopsy.Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clinical Nephrology 2010, 74: 440-5. PMID: 21084047, DOI: 10.5414/cnp74440.
  • Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 2010, 55: S1-13; quiz S14-9. PMID: 20420966, DOI: 10.1053/j.ajkd.2009.10.056.
  • MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reductionApplied Radiology. 2009; 38: 22-33
  • Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation.Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu-Alfa AK, Cowper SE, Bucala R, Gomer RH. Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. Journal Of Magnetic Resonance Imaging : JMRI 2009, 30: 1284-8. PMID: 19937928, PMCID: PMC2787835, DOI: 10.1002/jmri.21800.
  • Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis.Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK. Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 2009, 54: 538-41. PMID: 19237231, DOI: 10.1053/j.ajkd.2008.12.017.
  • Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA, TARGET Investigators.. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008, 23: 2311-8. PMID: 18310602, DOI: 10.1093/ndt/gfn026.
  • The association of Hashimoto disease and Congo red negative amyloidosis.Chaiban JT, Kalache SM, Abu Alfa AK, Shabb NS, Salti IS. The association of Hashimoto disease and Congo red negative amyloidosis. The American Journal Of The Medical Sciences 2008, 336: 293-6. PMID: 18794630, DOI: 10.1097/MAJ.0b013e31815b9d51.
  • The impact of NSF on the care of patients with kidney disease.Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. Journal Of The American College Of Radiology : JACR 2008, 5: 45-52. PMID: 18180009, DOI: 10.1016/j.jacr.2007.08.018.
  • The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis.Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Current Medical Research And Opinion 2008, 24: 1091-100. PMID: 18328118, DOI: 10.1185/030079908X280653.
  • Nephrogenic systemic fibrosis--implications for nephrologists.Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis--implications for nephrologists. European Journal Of Radiology 2008, 66: 208-12. PMID: 18342470, DOI: 10.1016/j.ejrad.2008.01.028.
  • Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007, 242: 647-9. PMID: 17213364, DOI: 10.1148/radiol.2423061640.
  • Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis?Saab G, Abu-Alfa A. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis? Radiology 2007, 244: 930-1; author reply 931-2. PMID: 17709844, DOI: 10.1148/radiol.2443070351.
  • Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?Saab G, Abu-Alfa A. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration? AJR. American Journal Of Roentgenology 2007, 189: W169. PMID: 17715089, DOI: 10.2214/AJR.07.2252.
  • Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology (Carlton, Vic.) 2006, 11: 142-6. PMID: 16669977, DOI: 10.1111/j.1440-1797.2006.00544.x.
  • Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration.Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. Journal Of The American Society Of Nephrology : JASN 2005, 16: 546-54. PMID: 15625070, DOI: 10.1681/ASN.2004090793.
  • Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. The New England Journal Of Medicine 2004, 350: 1516-25. PMID: 15071126, DOI: 10.1056/NEJMoa031633.
  • The ADEMEX study: Expanding the boundaries of peritoneal dialysis adequacy beyond small solute clearancesAbu-Alfa, A: The ADEMEX study: Expanding the boundaries of peritoneal dialysis adequacy beyond small solute clearances. Dialysis and Transplantation. 2003;(32):115-121.
  • CKD series: Evaluation and treatment of anemia in chronic kidney diseaseAbu-Alfa, A: CKD series: Evaluation and treatment of anemia in chronic kidney disease. Hospital Physician, 2003 (39), 31-38.
  • Addition of sertraline to other therapies to reduce dialysis-associated hypotension.Brewster UC, Ciampi MA, Abu-Alfa AK, Perazella MA. Addition of sertraline to other therapies to reduce dialysis-associated hypotension. Nephrology (Carlton, Vic.) 2003, 8: 296-301. PMID: 15012700, DOI: 10.1111/j.1440-1797.2003.00216.x.
  • Vascular access surveillance: evaluation of combining dynamic venous pressure and vascular access blood flow measurements.Hoeben H, Abu-Alfa AK, Reilly RF, Aruny JE, Bouman K, Perazella MA. Vascular access surveillance: evaluation of combining dynamic venous pressure and vascular access blood flow measurements. American Journal Of Nephrology 2003, 23: 403-8. PMID: 14566106, DOI: 10.1159/000074297.
  • Approach to fluid management in peritoneal dialysis: a practical algorithm.Abu-Alfa AK, Burkart J, Piraino B, Pulliam J, Mujais S. Approach to fluid management in peritoneal dialysis: a practical algorithm. Kidney International. Supplement 2002, S8-16. PMID: 12230477, DOI: 10.1046/j.1523-1755.62.s81.3.x.
  • Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine.Hoeben H, Abu-Alfa AK, Mahnensmith R, Perazella MA. Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 2002, 39: 102-7. PMID: 11774108, DOI: 10.1053/ajkd.2002.29887.
  • Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy.Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. The American Journal Of The Medical Sciences 2002, 323: 102-6. PMID: 11863077, DOI: 10.1097/00000441-200202000-00009.
  • Angiotensin-converting enzyme inhibitors and anemia in chronic kidney disease: a complex interaction.Abu-Alfa AK, Perazella MA. Angiotensin-converting enzyme inhibitors and anemia in chronic kidney disease: a complex interaction. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 2002, 39: 896-7. PMID: 11920360, DOI: 10.1053/ajkd.2002.32163.
  • Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate.Alappan R, Cruz D, Abu-Alfa AK, Mahnensmith R, Perazella MA. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 2001, 37: 294-9. PMID: 11157369, DOI: 10.1053/ajkd.2001.21292.
  • Prevalence of persistent asymptomatic proteinuria in HIV-infected outpatients and lack of correlation with viral load.Crowley ST, Cantwell B, Abu-Alfa A, Rigsby MO. Prevalence of persistent asymptomatic proteinuria in HIV-infected outpatients and lack of correlation with viral load. Clinical Nephrology 2001, 55: 1-6. PMID: 11200862.
  • ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.Abu-Alfa AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 2000, 35: 1076-82. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.
  • Reduction in arteriovenous graft impairment: results of a vascular access surveillance protocol.Cayco AV, Abu-Alfa AK, Mahnensmith RL, Perazella MA. Reduction in arteriovenous graft impairment: results of a vascular access surveillance protocol. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 1998, 32: 302-8. PMID: 9708617, DOI: 10.1053/ajkd.1998.v32.pm9708617.
  • Immunochemical characterization of Na+/H+ exchanger isoform NHE4.Pizzonia JH, Biemesderfer D, Abu-Alfa AK, Wu MS, Exner M, Isenring P, Igarashi P, Aronson PS. Immunochemical characterization of Na+/H+ exchanger isoform NHE4. The American Journal Of Physiology 1998, 275: F510-7. PMID: 9755122, DOI: 10.1152/ajprenal.1998.275.4.F510.
  • Monoclonal antibodies for high-resolution localization of NHE3 in adult and neonatal rat kidney.Biemesderfer D, Rutherford PA, Nagy T, Pizzonia JH, Abu-Alfa AK, Aronson PS. Monoclonal antibodies for high-resolution localization of NHE3 in adult and neonatal rat kidney. The American Journal Of Physiology 1997, 273: F289-99. PMID: 9277590, DOI: 10.1152/ajprenal.1997.273.2.F289.
  • Expression of Na(+)-H+ exchanger isoforms NHE1 and NHE3 in kidney and blood cells of rabbit and rat.Rutherford PA, Pizzonia JH, Biemesderfer D, Abu-Alfa A, Reilly R, Aronson PS. Expression of Na(+)-H+ exchanger isoforms NHE1 and NHE3 in kidney and blood cells of rabbit and rat. Experimental Nephrology 1997, 5: 490-7. PMID: 9438178.
  • Sodium-hydrogen exchange isoform expression in blood cells: implications for studies in diabetes mellitus.Rutherford P, Pizzonia J, Abu-Alfa A, Biemesderfer D, Reilly R, Aronson P. Sodium-hydrogen exchange isoform expression in blood cells: implications for studies in diabetes mellitus. Experimental And Clinical Endocrinology & Diabetes : Official Journal, German Society Of Endocrinology [and] German Diabetes Association 1997, 105 Suppl 2: 13-6. PMID: 9288535, DOI: 10.1055/s-0029-1211787.
  • Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 1996, 28: 535-40. PMID: 8840943, DOI: 10.1016/s0272-6386(96)90464-3.
  • Isolation and cDNA cloning of Ksp-cadherin, a novel kidney-specific member of the cadherin multigene family.Thomson RB, Igarashi P, Biemesderfer D, Kim R, Abu-Alfa A, Soleimani M, Aronson PS. Isolation and cDNA cloning of Ksp-cadherin, a novel kidney-specific member of the cadherin multigene family. The Journal Of Biological Chemistry 1995, 270: 17594-601. PMID: 7615566, DOI: 10.1074/jbc.270.29.17594.
  • NHE3: a Na+/H+ exchanger isoform of renal brush border.Biemesderfer D, Pizzonia J, Abu-Alfa A, Exner M, Reilly R, Igarashi P, Aronson PS. NHE3: a Na+/H+ exchanger isoform of renal brush border. The American Journal Of Physiology 1993, 265: F736-42. PMID: 8238556, DOI: 10.1152/ajprenal.1993.265.5.F736.
  • Uremic pancreopathy: impaired secretory function in vitro.Abu-Alfa A, Mujais SK. Uremic pancreopathy: impaired secretory function in vitro. American Journal Of Kidney Diseases : The Official Journal Of The National Kidney Foundation 1992, 20: 585-8. PMID: 1462987, DOI: 10.1016/s0272-6386(12)70223-8.
  • Gentamicin nephrotoxicity in extrahepatic cholestasis: modulation by dietary calcium.Vakil N, Abu-Alfa A, Mujais SK. Gentamicin nephrotoxicity in extrahepatic cholestasis: modulation by dietary calcium. Hepatology (Baltimore, Md.) 1989, 9: 519-24. PMID: 2925154, DOI: 10.1002/hep.1840090402.
  • Uremic exocrine pancreopathy.Abu-Alfa A, Ivanovich P, Mujais SK. Uremic exocrine pancreopathy. Nephron 1988, 48: 94-100. PMID: 3278247, DOI: 10.1159/000184885.
Edit Profile